Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Barbara Mason

    TitleAdjunct Professor
    SchoolUniversity of California, San Diego
    DepartmentPsychiatry
    Address9500 Gilman Drive #0603
    CA La Jolla 92093
    vCardDownload vCard

      Collapse Research 
      Collapse Research Activities and Funding
      Proof-of-Concept Human Laboratory Testing of Novel Drug Candidates Identified by INIA-NeuroImmune
      NIH/NIAAA U01AA025476Feb 1, 2017 - Jan 31, 2022
      Role: Principal Investigator
      Recent Frontiers and Advances in Drug Addiction (IDARS Conference)
      NIH/NIDA R13DA040432Aug 1, 2015 - Jul 31, 2016
      Role: Principal Investigator
      Glucocorticoid Antagonist Treatment of Alcohol Use Disorder
      NIH/NIAAA R01AA023152Sep 1, 2014 - Jun 30, 2019
      Role: Principal Investigator
      Pharmacological Treatment of Cannabis Withdrawal and Dependence
      NIH/NIDA R01DA030988Sep 30, 2010 - Jan 31, 2016
      Role: Principal Investigator
      Gabapentin Treatment of Cannabis Dependence
      NIH/NIDA R01DA026758Jul 15, 2009 - May 31, 2014
      Role: Principal Investigator
      TRANSLATIONAL CTR ON THE CLINICAL NEUROBIOL OF CANNABIS ADDICTION
      NIH/NIDA P20DA024194Sep 30, 2007 - Jun 30, 2012
      Role: Principal Investigator
      Gabapentin for Cannabis Withdrawal and Use
      NIH/NIDA R21DA020766May 1, 2006 - Oct 30, 2008
      Role: Principal Investigator
      Duloxetine versus Pregabalin for Treatment of Alcohol Dependence
      NIH/NIAAA R37AA014028Mar 1, 2003 - Aug 31, 2014
      Role: Principal Investigator
      Medication Development for Protracted Abstinence in Alcoholism
      NIH/NIAAA R01AA012602Sep 25, 1999 - Jun 30, 2016
      Role: Principal Investigator
      BEHAVIORAL/PHARMACOLOGIC TREATMENT OF ALCOHOLISM
      NIH/NIAAA U10AA011727Sep 30, 1997 - Aug 31, 2005
      Role: Co-Principal Investigator
      NALMEFENE IN NICOTINE AND ALCOHOL DEPENDENCE
      NIH/NIAAA R01AA011210Sep 29, 1996 - May 31, 2005
      Role: Principal Investigator
      NALMEFENE MAINTENANCE TREATMENT OF ALCOHOLISM
      NIH/NIAAA R01AA010518Apr 1, 1995 - Mar 31, 2002
      Role: Principal Investigator
      NALMEFENE MODIFICATION OF ALCOHOLISM
      NIH/NIAAA R01AA009560Sep 30, 1992 - Aug 31, 1996
      Role: Principal Investigator
      DESIPRAMINE METABOLISM IN RECOVERING ALCOHOLICS
      NIH/NIAAA R01AA008111Jan 1, 1990 - Dec 31, 1993
      Role: Principal Investigator
      LONGTERM ANTIDEPRESSANT TREATMENT OF ALCOHOLISM
      NIH/NIAAA R23AA006866Mar 1, 1987 - Feb 28, 1991
      Role: Principal Investigator
      CNS Effects of Alcohol: Cellular Neurobiology
      NIH/NIAAA P60AA006420Dec 1, 1983 - Dec 31, 2017
      Role: Principal Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Mason B. Emerging pharmacotherapies for alcohol use disorder. Neuropharmacology. 2017 Aug 01; 122:244-253. PMID: 28454983.
        View in: PubMed
      2. Salaheddin K, Mason B. Identifying barriers to mental health help-seeking among young adults in the UK: a cross-sectional survey. Br J Gen Pract. 2016 Oct; 66(651):e686-92. PMID: 27688518.
        View in: PubMed
      3. Koob GF, Mason B. Existing and Future Drugs for the Treatment of the Dark Side of Addiction. Annu Rev Pharmacol Toxicol. 2016 Jan 6; 56:299-322. PMID: 26514207.
        View in: PubMed
      4. Vendruscolo LF, Estey D, Goodell V, Macshane LG, Logrip ML, Schlosburg JE, McGinn MA, Zamora-Martinez ER, Belanoff JK, Hunt HJ, Sanna PP, George O, Koob GF, Edwards S, Mason B. Glucocorticoid receptor antagonism decreases alcohol seeking in alcohol-dependent individuals. J Clin Invest. 2015 Aug 3; 125(8):3193-7. PMID: 26121746.
        View in: PubMed
      5. Mason B. Acamprosate, alcoholism, and abstinence. J Clin Psychiatry. 2015 Feb; 76(2):e224-5. PMID: 25742214.
        View in: PubMed
      6. Perney P, Rigole H, Mason B, Dematteis M, Lehert P. Measuring sleep disturbances in patients with alcohol use disorders: a short questionnaire suitable for routine practice. J Addict Med. 2015 Jan-Feb; 9(1):25-30. PMID: 25629883.
        View in: PubMed
      7. Mason B, Goodell V, Shadan F. Gabapentin treatment for alcohol dependence--reply. JAMA Intern Med. 2014 Jul; 174(7):1201-2. PMID: 25003890.
        View in: PubMed
      8. Araos P, Pedraz M, Serrano A, Lucena M, Barrios V, García-Marchena N, Campos-Cloute R, Ruiz JJ, Romero P, Suárez J, Baixeras E, de la Torre R, Montesinos J, Guerri C, Rodríguez-Arias M, Miñarro J, Martínez-Riera R, Torrens M, Chowen JA, Argente J, Mason B, Pavón FJ, Rodríguez de Fonseca F. Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity. Addict Biol. 2015 Jul; 20(4):756-72. PMID: 24854157.
        View in: PubMed
      9. Mason B, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014 Jan 1; 174(1):70-7. PMID: 24190578.
        View in: PubMed
      10. Mason B, Higley AE. A translational approach to novel medication development for protracted abstinence. Curr Top Behav Neurosci. 2013; 13:647-70. PMID: 22351425.
        View in: PubMed
      11. Mason B, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S. A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. Neuropsychopharmacology. 2012 Jun; 37(7):1689-98. PMID: 22373942.
        View in: PubMed
      12. Perney P, Lehert P, Mason B. Sleep disturbance in alcoholism: proposal of a simple measurement, and results from a 24-week randomized controlled study of alcohol-dependent patients assessing acamprosate efficacy. Alcohol Alcohol. 2012 Mar-Apr; 47(2):133-9. PMID: 22218671.
        View in: PubMed
      13. Higley AE, Koob GF, Mason B. Treatment of alcohol dependence with drug antagonists of the stress response. Alcohol Res. 2012; 34(4):516-21. PMID: 23584117; PMCID: PMC3860394.
      14. Mason B, Lehert P. Acamprosate for alcohol dependence: a sex-specific meta-analysis based on individual patient data. Alcohol Clin Exp Res. 2012 Mar; 36(3):497-508. PMID: 21895717; NIHMSID: NIHMS334739.
        View in: PubMed
      15. Higley AE, Crane NA, Spadoni AD, Quello SB, Goodell V, Mason B. Craving in response to stress induction in a human laboratory paradigm predicts treatment outcome in alcohol-dependent individuals. Psychopharmacology (Berl). 2011 Nov; 218(1):121-9. PMID: 21607563; NIHMSID: NIHMS308592.
        View in: PubMed
      16. Crean RD, Tapert SF, Minassian A, Macdonald K, Crane NA, Mason B. Effects of chronic, heavy cannabis use on executive functions. J Addict Med. 2011 Mar; 5(1):9-15. PMID: 21643485.
        View in: PubMed
      17. Crean RD, Crane NA, Mason B. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011 Mar; 5(1):1-8. PMID: 21321675; NIHMSID: NIHMS266295.
        View in: PubMed
      18. Mason B, Lehert P. The effects of current subsyndromal psychiatric symptoms or past psychopathology on alcohol dependence treatment outcomes and acamprosate efficacy. Am J Addict. 2010 Mar-Apr; 19(2):147-54. PMID: 20163387.
        View in: PubMed
      19. Mason B, Heyser CJ. Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependence. CNS Neurol Disord Drug Targets. 2010 Mar; 9(1):23-32. PMID: 20201812.
        View in: PubMed
      20. Mason B, Heyser CJ. The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence. Expert Opin Drug Saf. 2010 Jan; 9(1):177-88. PMID: 20021295.
        View in: PubMed
      21. Reid IR, Ames R, Mason B, Bolland MJ, Bacon CJ, Reid HE, Kyle C, Gamble GD, Grey A, Horne A. Effects of calcium supplementation on lipids, blood pressure, and body composition in healthy older men: a randomized controlled trial. Am J Clin Nutr. 2010 Jan; 91(1):131-9. PMID: 19906800.
        View in: PubMed
      22. Mason B, Shaham Y, Weiss F, Le AD. Stress, alcohol craving, and relapse risk: mechanisms and viable treatment targets. Alcohol. 2009 Nov; 43(7):541-3. PMID: 19913197; NIHMSID: NIHMS162836.
        View in: PubMed
      23. Mason B, Lehert P. Effects of nicotine and illicit substance use on alcoholism treatment outcomes and acamprosate efficacy. J Addict Med. 2009 Sep; 3(3):164-71. PMID: 21769013.
        View in: PubMed
      24. Koob GF, Kenneth Lloyd G, Mason B. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat Rev Drug Discov. 2009 Jun; 8(6):500-15. PMID: 19483710; NIHMSID: NIHMS140631.
        View in: PubMed
      25. Mason B, Light JM, Williams LD, Drobes DJ. Proof-of-concept human laboratory study for protracted abstinence in alcohol dependence: effects of gabapentin. Addict Biol. 2009 Jan; 14(1):73-83. PMID: 18855801; NIHMSID: NIHMS145707.
        View in: PubMed
      26. Mason B, Light JM, Escher T, Drobes DJ. Effect of positive and negative affective stimuli and beverage cues on measures of craving in non treatment-seeking alcoholics. Psychopharmacology (Berl). 2008 Sep; 200(1):141-50. PMID: 18604601; NIHMSID: NIHMS145720.
        View in: PubMed
      27. Mason B, Crean R. Acamprosate in the treatment of alcohol dependence: clinical and economic considerations. Expert Rev Neurother. 2007 Nov; 7(11):1465-77. PMID: 17997696.
        View in: PubMed
      28. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason B, Mattson ME, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006 May 3; 295(17):2003-17. PMID: 16670409.
        View in: PubMed
      29. Mason B, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006 Aug; 40(5):383-93. PMID: 16546214.
        View in: PubMed
      30. Johnson BA, Koob GF, Schuckit MA, Mason B, Ait-Daoud N. Understanding and treating alcohol dependence. Alcohol Clin Exp Res. 2006 Mar; 30(3):567-84. PMID: 16499499.
        View in: PubMed
      31. Kranzler HR, Mueller T, Cornelius J, Pettinati HM, Moak D, Martin PR, Anthenelli R, Brower KJ, O'Malley S, Mason B, Hasin D, Keller M. Sertraline treatment of co-occurring alcohol dependence and major depression. J Clin Psychopharmacol. 2006 Feb; 26(1):13-20. PMID: 16415699.
        View in: PubMed
      32. Mason B. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother. 2005 Oct; 6(12):2103-15. PMID: 16197362.
        View in: PubMed
      33. O'Malley SS, Martin DJ, Hosking JD, Mason B. How pilot studies improve large-scale clinical trials: lessons learned from the COMBINE Study. J Stud Alcohol Suppl. 2005 Jul; (15):66-71; discussion 65. PMID: 16223058.
        View in: PubMed
      34. Mason B. Rationale for combining acamprosate and naltrexone for treating alcohol dependence. J Stud Alcohol Suppl. 2005 Jul; (15):148-56; discussion 140. PMID: 16223066.
        View in: PubMed
      35. Reid IR, Horne A, Mason B, Ames R, Bava U, Gamble GD. Effects of calcium supplementation on body weight and blood pressure in normal older women: a randomized controlled trial. J Clin Endocrinol Metab. 2005 Jul; 90(7):3824-9. PMID: 15827103.
        View in: PubMed
      36. Mason B. Acamprosate and naltrexone treatment for alcohol dependence: an evidence-based risk-benefits assessment. Eur Neuropsychopharmacol. 2003 Dec; 13(6):469-75. PMID: 14636963.
        View in: PubMed
      37. Mason B. Acamprosate. Recent Dev Alcohol. 2003; 16:203-15. PMID: 12638639.
        View in: PubMed
      38. Mason B, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, Hunter JA, Boyeson MG. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology. 2002 Oct; 27(4):596-606. PMID: 12377396.
        View in: PubMed
      39. Xie S, Suckow RF, Mason B, Allen D, Cooper TB. Rapid and sensitive determination of nalmefene in human plasma by gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Jun 25; 773(2):143-9. PMID: 12031840.
        View in: PubMed
      40. Koob GF, Mason B, De Witte P, Littleton J, Siggins GR. Potential neuroprotective effects of acamprosate. Alcohol Clin Exp Res. 2002 Apr; 26(4):586-92. PMID: 11981137.
        View in: PubMed
      41. Boening JA, Lesch OM, Spanagel R, Wolffgramm J, Narita M, Sinclair D, Mason B, Wiesbeck GA. Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials. Alcohol Clin Exp Res. 2001 May; 25(5 Suppl ISBRA):127S-131S. PMID: 11391061.
        View in: PubMed
      42. Mason B. Treatment of alcohol-dependent outpatients with acamprosate: a clinical review. J Clin Psychiatry. 2001; 62 Suppl 20:42-8. PMID: 11584875.
        View in: PubMed
      43. Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, Okano GJ, Ellis S, Covey D, Mason B, Jue S, Carmichael J, Guthrie K, Sloboda L, Dombrowski R, Geraets DR, Amato MG. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000 Oct; 20(10):1149-58. PMID: 11034037.
        View in: PubMed
      44. Mason B, Ownby RL. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectr. 2000 Feb; 5(2):58-69. PMID: 18296999.
        View in: PubMed
      45. Mason B, Salvato FR, Williams LD, Ritvo EC, Cutler RB. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry. 1999 Aug; 56(8):719-24. PMID: 10435606.
        View in: PubMed
      46. Mason B, Kocsis JH, Melia D, Khuri ET, Sweeney J, Wells A, Borg L, Millman RB, Kreek MJ. Psychiatric comorbidity in methadone maintained patients. J Addict Dis. 1998; 17(3):75-89. PMID: 9789161.
        View in: PubMed
      47. Mason B, Blackburn KH. Possible serotonin syndrome associated with tramadol and sertraline coadministration. Ann Pharmacother. 1997 Feb; 31(2):175-7. PMID: 9034418.
        View in: PubMed
      48. Johnson BA, Jasinski DR, Galloway GP, Kranzler H, Weinreib R, Anton RF, Mason B, Bohn MJ, Pettinati HM, Rawson R, Clyde C. Ritanserin in the treatment of alcohol dependence--a multi-center clinical trial. Ritanserin Study Group. Psychopharmacology (Berl). 1996 Nov; 128(2):206-15. PMID: 8956382.
        View in: PubMed
      49. Mason B. Dosing issues in the pharmacotherapy of alcoholism. Alcohol Clin Exp Res. 1996 Oct; 20(7 Suppl):10A-16A. PMID: 8904989.
        View in: PubMed
      50. Mason B, Kocsis JH, Ritvo EC, Cutler RB. A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. JAMA. 1996 Mar 13; 275(10):761-7. PMID: 8598592.
        View in: PubMed
      51. Williams LD, Mason B, Goldberg G, Cutler RB. Women and minorities representation in alcoholism treatment research. Psychopharmacol Bull. 1996; 32(2):201-4. PMID: 8783889.
        View in: PubMed
      52. Salvato FR, Mason B. Changes in transaminases over the course of a 12-week, double-blind nalmefene trial in a 38-year-old female subject. Alcohol Clin Exp Res. 1994 Oct; 18(5):1187-9. PMID: 7847604.
        View in: PubMed
      53. Mason B, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, Mantero-Atienza E. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res. 1994 Oct; 18(5):1162-7. PMID: 7847600.
        View in: PubMed
      54. Mason B, Kocsis JH. Desipramine in the treatment of depressed alcoholics. Am J Psychiatry. 1994 Aug; 151(8):1248. PMID: 8037266.
        View in: PubMed
      55. Mason B, Kocsis JH. Desipramine treatment of alcoholism. Psychopharmacol Bull. 1991; 27(2):155-61. PMID: 1924663.
        View in: PubMed
      56. Mason B, Kocsis JH, Frances AJ, Mann JJ. Amoxapine versus amitriptyline for continuation therapy of depression. J Clin Psychopharmacol. 1990 Oct; 10(5):338-43. PMID: 2258450.
        View in: PubMed
      57. Kocsis JH, Mason B, Frances AJ, Sweeney J, Mann JJ, Marin D. Prediction of response of chronic depression to imipramine. J Affect Disord. 1989 Nov-Dec; 17(3):255-60. PMID: 2529294.
        View in: PubMed
      58. Kocsis JH, Frances AJ, Voss C, Mann JJ, Mason B, Sweeney J. Imipramine treatment for chronic depression. Arch Gen Psychiatry. 1988 Mar; 45(3):253-7. PMID: 3277579.
        View in: PubMed
      59. Escobar JI, Mann JJ, Keller J, Wilkins J, Mason B, Mills MJ. Comparison of injectable molindone and haloperidol followed by oral dosage forms in acutely ill schizophrenics. J Clin Psychiatry. 1985 Aug; 46(8 Pt 2):15-9. PMID: 3894337.
        View in: PubMed
      60. MacLennan WJ, Martin P, Mason B. Protein intake and serum albumin levels in the elderly. Gerontology. 1977; 23(5):360-7. PMID: 852664.
        View in: PubMed
      61. MacLennan WJ, Coombe NB, Martin P, Mason B. The relationship of laboratory parameters to dietary intake in a long-stay hospital. Age Ageing. 1975 Nov; 4(4):189-94. PMID: 830074.
        View in: PubMed
      62. MacLennan WJ, Martin P, Mason B. Causes for reduced dietary intake in a long-stay hospital. Age Ageing. 1975 Aug; 4(3):175-80. PMID: 1211304.
        View in: PubMed
      63. MacLennan WJ, Martin P, Mason B. Energy intake, disability, disease and skinfold thickness in a long-stay hospital. Gerontol Clin (Basel). 1975; 17(3):173-80. PMID: 810391.
        View in: PubMed
      Barbara's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department